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The development of suitable radioligands for targeting CCK-2 receptor expressing tumors, such as medullary thyroid carcinoma,
is of great clinical interest. In the search for the best CCK-2R binding peptides, we have synthesized, evaluated and compared
the CCK8 peptide (Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe–NH2) and two gastrin analogs commonly referred to as MG0 (DGlu-
Glu(5)-Ala-Tyr-Gly-Trp-Met-Asp-Phe–NH2) and MG11 (DGlu(1)-Ala-Tyr-Gly-Trp-Met-Asp-Phe–NH2). The N-terminal portion of
the three peptide sequences was derivatized by introducing the DTPAGlu or DOTA chelators to allow radiolobeling with
111In(III) and 68Ga(III), respectively. Saturation binding and cellular internalization experiments were performed on A431 cells
overexpressing CCK2R (A431-CCK2R). All compounds showed Kd values in the nM range and were internalized with similar
rates in CCK2 receptor overexpressing cells. Biodistribution experiments showed higher specific uptake of both MG0-based
compounds compared to conjugates containing the CCK8 and MG11 peptide sequences. The higher retention levels of MG0-
based peptides were associated with markedly elevated and undesired kidney uptake compared to the other compounds.
Current indications suggest that the 5 Glu N-terminal residues while improving peptide stability and receptor-mediated tumor
uptake cause unacceptably high kidney retention. Although displaying lower absolute tumor uptake values, the DOTA-coupled
CCK8 peptide provided the best tumor to kidney uptake ratio and appears more suitable as lead compound for improvement
of radiopharmaceutical properties. Copyright c© 2011 European Peptide Society and John Wiley & Sons, Ltd.
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Introduction
A number of receptor systems are being evaluated in order to
develop peptide-based radiopharmaceuticals for diagnostic and
therapeutic purposes [1]. This field is of particular interest for ap-
plications in oncology. Many of these receptor systems have been
shown to be overexpressed in particular types of human cancers.
The naturally occurring ligands for these receptors are, in many
instances, small peptides. A number of potential receptor systems
that can be utilized as molecular targets are under investigation
[2]. An excellent example of the successful clinical application of
a peptide/receptor system has been the use of the radiolabeled
somatostatin analog, octreotide,which has beenutilized in a num-
ber of clinical studies to identify tumors and other pathological
conditions inwhich specific subtypes of the somatostatin receptor
are overexpressed [3]. This approach is also being extensively ap-
plied to the treatment of somatostatin receptor expressing tumors
with peptides labeled with β-emitters such as 90Y or 177Lu [4].
We are evaluating the CCK family of receptors. Twomajor CCK-R
subtype have been identified (CCK1R and CCK2R also referred
to as CCKAR and CCKBR, respectively). The CCK2R is the gastrin
receptor which promotes acid secretion in the fundal mucosa of
the stomach. The CCK-R is present in a number of different tissues
with rather selective expression of one or the other subtype. The
CCK1R subtype is expressed in the pancreas where it has been
found to be involved in enzyme secretion in pancreatic acini and
insulin secretion from islet cells. It is also found in the gall bladder
and other areas of smooth muscle in the gastrointestinal tract, in
thegastricmucosaand inselectareasof thecentralnervoussystem
such as vagal afferent neurons. CCK2R is expressed throughout the
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central nervous system as well as by various cell types of gastric
mucosa: parietal cells responsible for acid production; chief cells
responsible of pepsinogen production and enterochromaffin-like
cells producing histamine [5].
Overexpression of both of these receptor subtypes has been
demonstrated in certain human tumors [6]. The CCK1R has
been found to be overexpressed in a number of pancreatic
adenocarcinomas as well as in cell lines derived from such tumors
and to a smaller extent in GEP tumors. The CCK2R has been found
to be overexpressed in medullary thyroid cancers, as well as in
other tumors of neuroendocrine origin such as small cell lung
cancers and GEP tumors. The CCK2R has been found on cell lines
derived frommedullary thyroid carcinoma, such as the human cell
line TT.
There is particularly high incidence of CCK2R overexpression in
certain neuroendocrine tumors such as medullary thyroid cancer
(MTC, >90%) [6]. On this basis, development of CCK2R targeting
radiopharmaceuticals has gained relevant interest. A number of
CCK and gastrin derivatives, showing high affinity for the CCK2R,
have been characterized over the past years for the purpose
of in vivo receptor targeting. Among these, the C-terminal CCK
octapeptide amide (CCK26–33 or CCK8) is capable of binding
CCK2R and has been chosen by our group for the development
of CCK2R targeting ligands. Our initial work has characterized
the CCK8 peptide coupled to a DTPA derivative [7]. Behe and
Behr have evaluated DTPA-coupled derivatives of minigastrin for
CCK2R targeting [8–10]. Reubi described severalDTPA- andDOTA-
coupled CCK analogs [11] with high affinity for the CCK2R. One
of these analogs DTPA [D-Asp26, Nle28,31]CCK(26–33) has been
characterized in a rat tumor model [12] and in a clinical trial in
patients with MTC [13]. Derivatives of minigastrin labeled with
99mTc have also recently been evaluated [14] and some clinical
applications have also been described [15].
While specific targeting to CCK2R has been demonstrated with
most compounds tested to date, there are a number of issues that
may be improved for both imaging and therapeutic applications.
The use of positron emitters for imaging applications would
allow higher spatial resolution and sensitivity through the use of
PET. Imaging of somatostatin receptor expressing tumors with
DOTA-coupled octreotide derivatives such as DOTATOC labeled
with the positron emitter 68Ga appears more sensitive than 111In-
Octreoscan [16,17]. Furthermore, the quantitative nature of PET
scanning may allow more accurate calculations of tumor and
normal organ dosimetry in treatment planning. One major issue
encountered in the development of these peptides is the elevated
kidneyaccumulation thatmaycause toxicityproblems,particularly
in therapeutic applications. This appears to be a significant
problem with DTPA-coupled minigastrin [18,19] although co-
infusion of polyglutamic acid appears to greatly reduce kidney
accumulation [20]. Kidney accumulation, however, appears much
lower for DTPA-coupledCCKderivatives such as sulfatedCCK8 [18]
and DTPA[D-Asp26, Nle28,31]CCK (26–33) [12] and with DTPAGlu-
G-CCK8 tested by our group [7]. Nevertheless, initial clinical trials
utilizing 90Y labeled minigastrin [8] have been carried out and
have shown kidney and bone marrow toxicities.
When developing radiopharmaceuticals for tumor imaging and
radionuclide therapy,onemustfindthebestcompromisebetween
the highest possible uptake and retention in the target organ and
the lowest possible uptake and retention in non-target tissues. In
this work, we attempt tomake a direct comparison using the same
cellular binding assays and animal model between three known
CCK2R binding peptide sequences, one derived from CCK (CCK8)
and two derived from gastrin (MG0 and MG11). These peptide
sequences were coupled to two different chelators: one is the
DTPAGlu chelatorwhich is used for 111In labeling and forwhichwe
havepreviously reported in vitroand in vivopropertiesofDTPAGlu-
G-CCK8 [7]. Peptides labeled in this manner can be utilized for
gamma camera imaging applications. This chelating agent has
one more negatively charged carboxylic function compared to
DTPA commonly used in peptide labeling applications. The other
is the DOTA chelator that is widely used for applications in PET
using the short half-life positron emitter 68Ga and for radionuclide
therapy with β-emitting isotopes such as 90Y or 177Lu. The in vitro
and in vivo properties of these six derivatives were compared in
detail and the use of these compounds as radiopharmaceuticals is
presented.
Materials and Methods
Peptide Conjugate Synthesis
ProtectedNα-Fmoc-aminoacidderivatives, coupling reagents and
Rink amide MBHA resin were purchased from Inbios srl (Napoli,
Italy) and Calbiochem-Novabiochem (Lau¨felfingen, Switzerland).
[DTPAGlu(tBu)5] was prepared according to reported procedures
[21]. [DOTA(tBu)3] was purchased from Macrocyclics (Dallas, TX,
USA). The synthesis of DTPAGlu-G-CCK8 has been previously
reported [7]. All other chemicals were commercially available by
Sigma–Aldrich (Bucks, Switzerland) and were used as received
unless otherwise stated. Solid phase peptide synthesis was
performed on a 433A Applied Biosystems automatic synthesizer
(Foster City, CA, USA). Analytical RP-HPLC runs were carried out on
a HP Agilent Series 1100 apparatus (Santa Clara, CA, USA) using a
Phenomenex (Torrance, CA, USA) C18 column, 4.6 mm × 250 mm
with a flow rate of 1.0 ml/min. For all the RP-HPLC procedures, the
system solvent used was 0.1% TFA in water (A) and 0.1% TFA in
CH3CN (B). The column was eluted with two linear gradients at
1.0 ml/minflowrate from5to70%B in30 min followedby70–95%
B in10 min. Preparative RP-HPLCwas carriedoutonaShimadzu8A
(Kyoto, Japan) apparatus equipped with an UV Shimadzu detector
using a Phenomenex (Torrance, CA, USA) C4 column, 22 mm ×
250 mmwith a flow rate of 20 ml/min, elutedwith a linear gradient
of 0.1% TFA in water (A) and 0.1% TFA in CH3CN (B) as described
above at 20 ml/min flow rate. Mass spectral analyzes were carried
out on MALDI-TOF Voyager-DE mass spectrometer Perseptive
Biosystems (Framigham, MA, USA).
Peptide synthesis was carried out in solid phase under standard
conditions using Fmoc strategy on Rink amide MBHA resin. After
the assemblingof thepeptide sequences on the solid support, and
Fmoc removal from the N-terminal residue, two equivalents of the
full protected chelating agents [DTPAGlu(tBut)5] or [DOTA(tBu)3],
preactivatedwith twoequivalents of HATUand four equivalents of
DIPEA, dissolved in DMF, were added to the vessels. The coupling
time was 1 h under a N2 stream at room temperature.
The peptide derivatives were cleaved from the solid support by
suspending the resin in10 mlTFA/TIS/H2O(95.5/2/2.5) for120 min.
Free peptide derivatives were precipitated by adding cold ethyl
ether. The crude compounds were purified by preparative RP-
HPLC. Mass spectral analysis was carried out on MALDI-TOF. The
desired compounds were obtained at HPLC purity higher than
95% and in a final yield between 30 and 40%. The mass and HPLC
retention time are reported in Table 1.
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Table 1. Mass spectrometry and HPLC data of the studied minigastrins and CCK8 conjugates
Peptide conjugate Sequence Mass (amu) Rt (min)
DOTA-G-CCK8 DOTA-Gly-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe–NH2 (m/z) = 1520 17.9
DTPAGlu-G-CCK8 DTPAGlu-Gly-Asp-Tyr-Met-Gly-Trp-Met-Asp-Phe–NH2 (m/z) = 1566 24.6
DOTA-MG11 DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe–NH2 (m/z) = 1401 19.0
DTPAGlu-MG11 DTPAGlu-DGlu-Ala-Tyr-Gly-Trp-Met-Asp-Phe–NH2 (m/z) = 1485 20.5
DOTA-MG0 DOTA-DGlu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe–NH2 (m/z) = 2046 21.1
DTPAGlu-MG0 DTPAGlu-DGlu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe–NH2 (m/z) = 2130 21.1
Radiolabeling
Indium-111 was purchased from Covidien (Petten, NL, USA) in the
chemical formof [111In]Cl3 (740 MBq/ml). Gallium-68wasobtained
from an in-house 68Ge/68Ga generator, based on TiO2 phase (30
mCi, f-Con Pharma, Berlin). This type of 68Ge/68Ga radionuclide
generators yields ‘‘ionic’’ 68Ga3+ in 0.1 M HCl. This initial eluate
was adsorbed onto a cation exchange resin (Bio-Rad AG 50 W-X8
<400 mesh) [22] and washed with a 80% (CH3)2CO–0.15 M HCl
solution in order to remove possible impurities. Four hundred
microliters of a 98% (CH3)2CO–0.05 M HCl solution was slowly
flowed through the resin in order to recover the 68Ga3+. This
fraction was used directly for labeling.
All peptide conjugates were dissolved in H2O containing 20%
CH3CN at a concentration of 0.1–1 mM for radiolabeling. All
solutionswerepreparedbyweight, and theirmolar concentrations
measured by UV–vis spectrometry.
For labeling of the DTPAGlu-coupled conjugates with 111In,
the solution of [111In]Cl3 was buffered by adding 10 volumes
of 0.3 M sodium citrate immediately prior to labeling. The
peptide–conjugate solution was then mixed with 10 volumes
of [111In]citrate to a final concentration of peptide between 1 and
10 µM and incubated for at least 1 h at room temperature.
Gallium-68 labeling of DOTA-coupled conjugates was carried
out in pure water, the processed activity was added to preheated
water (3.8 ml) in an open standard glass vial containing 15 µl
(10 µg) of DOTA-coupled peptide. Radiolabeling was performed
in a heating block set at 124 ◦C for 10 min. The reaction mixture
was passed through a small C18 cartridge (Phenomenex Strata-X
Tubes, 30 mg). After washing the cartridge with 5 ml of H2O, the
68Ga-labeled peptide was recovered with 400 µl of pure ethanol,
dissolved in0.9%saline solutionandsterilizedbyfiltration through
a 0.22 µm membrane filter. For all peptide conjugates, labeling
efficiency was determined by silica gel-TLC using 0.3 M Na-citrate
as eluent, or RP-HPLCwhichwasperformedonaGilson 305 system
(Gilson Inc. Middleton, WI, USA) with an analytical Vydac C18 col-
umnconnected to aBeckman170 radiodetector (BeckmanCoulter
Inc. Brea, CA, USA), using an H2O/0.1% TFA and CH3CN/0.1% TFA
gradient (5–70% CH3CN in 18 min, flow rate 0.9 ml/min).
Binding and Cellular Internalization Experiments
In vitro cellular assays were performed on A431 cells that had
been stably transfected with the plasmid pCR3.1 containing
the full coding sequence for the human CCK2R [7]. Cells were
maintained in medium containing the neomycin analog G418 at
a concentration of 500 µg/ml. Binding assays were performed on
cells that had been plated at a density of 1–200 000 cells/well
in 12-well multi-well plates 2 or 3 days prior to the experiments.
These conditions allowed for the cells to be almost confluent at
the time of the assay. To assess binding affinity of the different
compounds, duplicate wells were incubated with serial dilutions
of labeled conjugates in culture medium at 4 ◦C for 1 h, with
concentrations ranging from 0.5 to 500 nM. To assess non-specific
binding, 100–1000-fold excess unlabeled peptide was added to
some of the wells. Cell-associated radioactivity was recovered
from the wells by trypsinization after two rapid washes in ice-cold
PBS. Radioactivity was then counted, normalized for the number
of cells and non-specific binding was subtracted. Binding curves
were analyzed using a Macintosh computer and Kaleidagraph
software (Abelbeck Software, Version 3.0.5, distributed by Synergy
Software, Reading, PA, USA). Dissociation constants (Kd) and
apparent number of binding sites per cell (Bmax) were derived
by fitting the data to the following equation:
Bound = Bmax × [peptide conjugate]
Kd + [peptide conjugate] .
Cellular internalization was determined by comparing differences
in accumulation of the compound incubated with A431-CCK2R
cells at 4 ◦C, temperature at which most metabolic processes are
blocked, and at 37 ◦C, where all metabolic processes including
receptor internalization are active. Cells were incubated with a
fixed concentration of the peptide conjugate (15 nM in culture
medium) at the two temperatures, for 60 and 120 min. After
120 min of incubation, somewells were rinsedwith PBS to remove
unbound radioactivity and were subsequently incubated for an
additional hour at 4 ◦C with 15 µM unlabeled peptide, in order to
displace any surface-bound radioactivity. Radioactivity associated
to cellswas determined afterwashing awayunbound radioactivity
and subsequently normalized for protein content.
Biodistribution and Imaging Experiments in Mice
Mice bearing xenografts of A431-CCK2R and A431-control cells
were generated by injecting 100 µl of the respective cell
suspensionsat adensityof 2×107/ml inPBS inoppositeflanksof 6-
week-old CD-1 nudemice (weight 17–23 g). Tumorswere allowed
to grow for 10–14 days. Final tumor weight was between 0.5 and
1 g at the time of the biodistribution and imaging experiments.
Tissue and tumor distribution of the radiolabeled compounds
was determined 1 h following tail vein injection of labeled
peptide in the lateral tail vein (n ≥ 5 animals per compound,
0.5–2 nmol peptide). Blood, lungs, liver, spleen, kidneys, stomach,
intestines, muscle and xenograft samples were weighed and
radioactivity determined in the gamma counter. Dilutions of the
injected compound were simultaneously counted for accurate
determination of the injected dose. The relative amount of
radioactivity in the organs was calculated and expressed as
percentage of the injected dose/gram tissue (%ID/g) normalized
J. Pept. Sci. 2011; 17: 405–412 Copyright c© 2011 European Peptide Society and John Wiley & Sons, Ltd. wileyonlinelibrary.com/journal/jpepsci
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Figure 1. Structural formula of the peptide conjugates being characterized.
to a 20-g mouse. Imaging of 68Ga distribution was performed
in some animals using a SIEMENS ECAT47 clinical PET scanner
(Siemens, Knoxville, TN) in 2D mode with measured attenuation
correction (Siemens, Erlangen, Germany) in order to visualize
distribution in CCK2R positive tissues (one bed position, 5-min
scanning time).
Results and Discussion
Peptide Conjugate Synthesis
The peptide conjugates are based on native bioactive peptide
sequencesmodifiedontheN-terminus to link thechelatingagents.
The amino acid sequences of the three different peptides and the
chemical structures of the two chelating agents are reported in
Figure 1. Previous studies have demonstrated that modifications
onpeptideN-terminal functions donot affect the receptor binding
properties of the bioactive peptides [23]. The selected chelating
agents, DOTA andDTPAGlu, are capable of coordinating Ga3+ and
In3+ ions, respectively, with high affinity. DTPAGlu has one more
carboxylic function compared to the more frequently utilized
DTPA chelator. This feature improves stability of the indium
complex and increases the negative charge of the conjugate.
Therefore, peculiar biodistributionproperties ofDTPAGlu-coupled
peptides are expected relative to DTPA conjugated compounds.
The peptide conjugate syntheses were performed by solid phase
with Fmoc strategy following well established procedures. The
conjugates, characterized by mass spectrometry for identity and
HPLC for their purity, were obtained in high yields and high purity.
All compounds showed rapid and efficient labeling which was
in all cases above 95% based on the quality control performed
at the end of labeling. Figure 2 shows a typical radioactivity trace
from the labeling of DOTA-G-CCK8 with 68Ga (tR = 12 min.).
Figure 3(A) shows resultsof thebindingassaysperformedat4 ◦C
on A431 cells overexpressing the CCK2R with the DOTA-coupled
peptides. The saturationcurves showhighaffinity ligand–receptor
interaction and saturable binding with dissociation constants (Kd)
in the order of 10−8 M. Affinity measured for the DTPAGlu-coupled
peptides was very similar with DTPAGlu-MG0 showing a Kd of
25 ± 5 nM (mean ± SD) and DTPAGlu-MG11 yielding 30 ± 9 nM.
The Kd value for DTPAGlu-G-CCK8 in this same cell culture system
is 23± 4 nM [7]. Non-specific binding, as assessed by incubation of
the compound with non-receptor expressing cells or in receptor
expressing cells in the presence of 100-fold excess unlabeled
peptide, was very low for all compounds (not shown).
To evaluate if the peptides were being internalized by
the cells, we performed parallel experiments in which A431-
CCK2R cells were incubated with 15 nM labeled peptide at
4 ◦C (internalization blocked) or 37 ◦C (internalization active,
Figure 3(B)).All compoundstestedshowprogressiveaccumulation
wileyonlinelibrary.com/journal/jpepsci Copyright c© 2011 European Peptide Society and John Wiley & Sons, Ltd. J. Pept. Sci. 2011; 17: 405–412
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Figure 2. Radioactive trace of HPLC analysis of 68Ga-DOTA-G-CCK8
(tR = 12 min). Negligible amounts of free 68Ga metal are detectable.
of radiolabel in cells incubated at 37 ◦C with labeled peptide
alone, whereas, the levels of cell-associated radioactivity are
constant in cells incubated at 4 ◦C for 60 and 120 min, suggesting
that for all these compounds internalization is occurring to
some extent at 37 ◦C. Co-incubation with excess cold peptide
produced very low levels of cell-associated activity confirming
specificity of interaction. After incubation for 120 minwith labeled
peptide alone, cells were incubated with excess cold peptide
for 60 min at 4 ◦C. For all peptides, a large portion (80–95%)
of the cell-associated radioactivity, was displaced by addition of
the respective unlabeled peptide in cells previously incubated at
4 ◦C whereas a small amount (20–30%) was displaced in cells
previously incubated at 37 ◦C, suggesting that the majority of the
labeled peptide that is associated to cells has been internalized in
cells incubated at 37 ◦C. Data for the DTPAGlu-coupled peptides
is not shown.
Binding and internalization properties are very similar for the
six compounds being compared and in agreement with the
findings of other groups that have previously reported on similar
compounds of this class [24]. These properties alone do not allow
to single-out any particular compound which has more favorable
characteristics.
The data obtained in the biodistribution experiments is
displayed in Figure 4. Specific targeting of the A431-CCK2R
xenografts is evident for all the compounds being compared
as higher values of accumulation are observed in these tumors
compared to the control xenografts. The two Glu(5)-minigastrin
derivatives show the highest accumulation in the CCK2R positive
xenografts (2.9%ID/g for the 111In labeled DTPAGlu-coupled
derivative and 3.1%ID/g for the 68Ga labeled DOTA-coupled
compound). The higher target tumor accumulation of these two
(A)
(B)
Figure 3. (A) Saturation binding curves of 68Ga-DOTA-G-CCK8, 68Ga-DOTA-MG0 and 68Ga-DOTA MG11 on A431-CCK2R cells at 4 ◦C. There is similar
high affinity binding for all peptides tested. (B) Internalization of 68Ga-DOTA-G-CCK8, 68Ga-DOTA-MG0 and 68Ga-DOTA-MG11 on A431-CCK2R cells (see
Materials and Methods). There is progressive accumulation of activity in cells incubated at 37 ◦C compared to cells incubated at 4 ◦C with the same
compound. After accumulating radiolabeled peptide for 120 min (third set of bars from the left) addition of cold peptide at high concentrations (10 µM)
displaces virtually all radioactivity from cells previously incubated at 4 ◦C, whereasmost activity in cells incubated at 37 ◦C is not displaced indicating that
it is internalized. Co-incubation of hot and excess cold peptide producesminimal accumulation of radioactivity indicating specific receptor-mediated cell
uptake. There are virtually no differences in the biological behavior of the three peptides.
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Figure 4. Biodistribution of the six peptide conjugates 1 h after injection (n = 5 animals per time point) in nude mice bearing A431-CCK2R and control
xenografts.
Table 2. Summary of biodistribution properties at 1-h post-injection of the six peptides and binding affinities
Biodistribution at 1 h
post-injection
111In-DTPAGlu-
G-CCK8
111In-DTPAGlu-
MG0
111In-DTPAGlu-
MG11
68Ga-DOTA-
G-CCK8
68Ga-DOTA-
MG0
68Ga-DOTA-
MG11
Kidneys (%ID/g) 4.1 48.1 2.6 1.2 36.6 2.4
Receptor positive xenograft (%ID/g) 1.6 2.9 1.2 1.5 3.1 2.2
Control xenograft (%ID/g) 0.4 1.3 0.7 0.3 0.5 0.4
Positive xenograft/kidney ratio 0.4 0.1 0.4 1.3 0.1 0.9
Positive to control xenograft ratio 3.7 2.2 1.7 4.6 6.7 5.2
Binding affinity in vitro (Kd, nM) 23 25 30 12 22 28
compounds is likely related to longer circulation times perhaps
due to their higher in vivo stability as previously indicated [10].
This is also supported by the higher blood concentrations of
radioactivity observed for these two compounds at the time
point. One drawback, however, is that these two derivatives
show the highest levels of uptake in the kidneys (48.1%ID/g
and 36.6%ID/g respectively) which is undesired as high kidney
accumulation greatly increases the possibility of kidney toxicity in
clinical applications of radionuclide therapy. Furthermore, having
areas of very high activity concentration also impairs imaging
studies by creating artefacts that reduce picture quality. The high
kidney accumulation of peptides containing elevated number
of Glu residues is well known and appears related to the high
concentration of negative charges on the peptide [18,19]. There
are several reports on how this undesired renal accumulation can
be reducedby co-injectionof large amounts of negatively charged
amino-acids [20] or other compounds [25].
The MG11 and CCK8 derivatives show very similar biodistribu-
tion features. For these compounds kidney accumulation is much
lower than for the MG0 derivatives. One marked improvement
of [68Ga]DOTA-G-CCK8 compared to the previously published
[111In]-DTPAGlu-G-CCK8 [7] was found to be its extremely low
kidney retention (1.2% vs 4.1% ID/g, respectively). Target tumor
accumulation also occurs at lower levels for these derivatives
compared to the two MG0-based peptides.
Accumulation of the compounds in the remaining organs,
including the liver that is a major route of excretion of lipophilic
compounds and metabolites, was negligible. For all compounds,
the bulk of the excess radioactivity appears to be cleared through
the kidneys, i.e. in general, a desired feature as it is more rapid
than hepatobiliary clearance, although there is extremely high
retention of the MG0 derivatives in the kidneys as pointed out
earlier. Compounds that have prevailing hepatobiliary clearance
are retained in the gut for prolonged periods of time making it
difficult to identify areas of specific uptake in the abdomen using
imaging techniques, and are thus less desirable.
The side by side comparison of the in vitro and in vivo properties
of the six compounds being evaluated is summarized in Table 2. It
appears that the DOTA-coupled derivatives show in general lower
retention in the control xenografts compared to the DTPAGlu-
coupledcounterparts. This canbeappreciated in the line regarding
the positive xenograft to control xenograft ratio where it is clear
thathighervaluesareobservedfor theDOTA-coupledcompounds.
The lower background radioactivity seen with DOTA-coupled
compounds may be related to the radioisotope utilized. The
111In labeled metabolites derived from metabolic breakdown of
the peptides may have different biological behaviors than 68Ga
breakdown products. It is well known that small quantities of
111In may be chelated by iron-binding proteins such as transferrin
[26]. The long plasma half-life of this protein may be causing the
slightly higher background radioactivity levels compared to the
68Ga labeled compounds. Other possibilities include more rapid
clearance of [68Ga]DOTA-coupled metabolites relative to [111In]
DTPAGlu breakdown products.
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Figure 5. MIP-PET images obtained after injection of the three 68Ga-
labeled compounds. The A431-CCK2R expressing xenografts (+) and
control xenografts (−) are located in opposite thighs of the animals.
Concentration in the kidneys (K) is much higher for the 68Ga-DOTA-MG0
compound compared to the other two peptides.
The 68Ga labeled DOTA-coupled compounds appear in general
to have better characteristics compared to the 111In labeled
compounds. Figure 5 showsMIP images fromPET scansperformed
on the animals at 1-h post-injection of the three 68Ga labeled
compounds. The animals bear tumors on both flanks; however,
in all cases only the CCK2R positive tumor (right flank) is visible
compared to the background activity. The only other areas of
significant activity visible in these images are the kidneys and the
bladder in some cases. The [68Ga]DOTA-MG0 compound shows
remarkable concentration in the kidneys. This markedly high
uptake greatly reduces the contrast between the CCK2R positive
tumor and the kidneys. Furthermore, it seems like the entire
abdominal cavity is occupied by this non-specific uptake due to
the spill-over effect caused by the very high concentration of
radioactivity relative to the other organs. The MG0 compounds
therefore appear less useful than the MG11- and CCK8-based
compounds at least for the purpose of imaging.
Another advantage of the use of DOTA-coupled compounds is
the ability to image their distribution with PET by using isotopes
such as 68Ga as in this manuscript. This allows more accurate
localization of areas of concentration and accurate quantitative
measurements of radioactivity in tissues of interest. Furthermore,
the same compound labeled with a different isotope may be
utilized for radionuclide therapy giving the advantage of utilizing
a single agent that can be radiolabeled with different isotopes
based on the intended application.
Selection of an ideal peptide-based radiopharmaceutical for nu-
clear imagingor for radionuclide therapy reliesonacombinationof
different characteristics where the best possible trade-off must be
accepted. Imaging and therapy have different requirements in the
biological characteristics of the radiopharmaceuticals utilized. In
imaging applications, the absolute amount of radioactivity that is
concentrated in a lesionor target tissueof interest is less important
compared to radionuclide therapy, where tumor absorbed doses
are directly related to how much radioactivity is concentrated in
the given tissue. Successful imaging compounds rely more on
the contrast between target and non-target tissues rather than
absolute radioactivity concentration values. Furthermore, in ra-
dionuclide therapy, the time course of radioactivity concentration
in the target tissueplays a key role indeterminingoverall absorbed
dose. Absorbeddose is dependent on the integrated activity in the
tissue over time. Therefore, high uptake in a lesion at an early time
point, while suitable for lesion detection in imaging applications,
is not sufficient to guarantee elevated absorbed doses. Prolonged
elevated retention of the radiolabeled compound is more impor-
tant for therapeutic applications whereas high contrast between
target and non-target tissues is necessary for imaging.
It has become apparent over the past few years that the major
issue in thedevelopment of CCK2R targeted radiopharmaceuticals
is how to best compromise between tumor and kidney concentra-
tions.Mather et al. have recently describeda comparisonof several
radiolabeled peptides that they have analyzed and selected based
on the tumor to kidney uptake ratio [27]. Of the six compounds
we compared in the currentmanuscript, only [68Ga]DOTA-G-CCK8
shows higher uptake in the CCK2R positive xenograft compared
to kidney (Table 2). This compound therefore appears to be most
promising for imaging applications although improvement of
the tumor uptake properties may be necessary to improve the
possibility of radionuclide therapy applications.
Conclusions
We have directly compared the biological behavior of six
radiolabeledpeptidederivatives targeting theCCK2R.Ourfindings
suggest that among the compounds we have tested [68Ga]DOTA-
G-CCK8 is the most promising for further development.
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